Terms: = Liver cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Treatment
24 results:
1. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
2. Serum Biomarkers of Nociceptive and Neuropathic Pain in Chronic Pancreatitis.
Saloman JL; Li Y; Stello K; Li W; Li S; Phillips AE; Hall K; Fogel EL; Vege SS; Li L; Andersen DK; Fisher WE; Forsmark CE; Hart PA; Pandol SJ; Park WG; Topazian MD; Van Den Eeden SK; Serrano J; Conwell DL; Yadav D;
J Pain; 2023 Dec; 24(12):2199-2210. PubMed ID: 37451493
[TBL] [Abstract] [Full Text] [Related]
3. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.
Giraldez MD; Carneros D; Garbers C; Rose-John S; Bustos M
Nat Rev Gastroenterol Hepatol; 2021 Nov; 18(11):787-803. PubMed ID: 34211157
[TBL] [Abstract] [Full Text] [Related]
4. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.
Lu G; Tian S; Sun Y; Dong J; Wang N; Zeng J; Nie Y; Wu K; Han Y; Feng B; Shang Y
Theranostics; 2021; 11(5):2460-2474. PubMed ID: 33500736
[No Abstract] [Full Text] [Related]
5. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract] [Full Text] [Related]
6. Postoperative adjuvant treatment strategy for hepatocellular carcinoma with microvascular invasion: a non-randomized interventional clinical study.
Wang L; Wang W; Rong W; Li Z; Wu F; Liu Y; Zheng Y; Zhang K; Siqin T; Liu M; Chen B; Wu J
BMC Cancer; 2020 Jul; 20(1):614. PubMed ID: 32611327
[TBL] [Abstract] [Full Text] [Related]
7. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation.
Choi GH; Kim GA; Choi J; Han S; Lim YS
Aliment Pharmacol Ther; 2019 Jul; 50(2):215-226. PubMed ID: 31135074
[TBL] [Abstract] [Full Text] [Related]
8. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma.
Ma H; Yan D; Wang Y; Shi W; Liu T; Zhao C; Huo S; Duan J; Tao J; Zhai M; Luo P; Guo J; Tian L; Mageta L; Jou D; Zhang C; Li C; Lin J; Lv J; Li S; Lin L
Cancer Sci; 2019 Mar; 110(3):950-961. PubMed ID: 30648776
[TBL] [Abstract] [Full Text] [Related]
9. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma.
Mi F; Gong L
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28659496
[TBL] [Abstract] [Full Text] [Related]
10. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/gp130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract] [Full Text] [Related]
11. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC; Couchy G; Balabaud C; Morcrette G; Caruso S; Blanc JF; Bacq Y; Calderaro J; Paradis V; Ramos J; Scoazec JY; Gnemmi V; Sturm N; Guettier C; Fabre M; Savier E; Chiche L; Labrune P; Selves J; Wendum D; Pilati C; Laurent A; De Muret A; Le Bail B; Rebouissou S; Imbeaud S; ; Bioulac-Sage P; Letouzé E; Zucman-Rossi J
Gastroenterology; 2017 Mar; 152(4):880-894.e6. PubMed ID: 27939373
[TBL] [Abstract] [Full Text] [Related]
12. IL-6 pathway in the liver: From physiopathology to therapy.
Schmidt-Arras D; Rose-John S
J Hepatol; 2016 Jun; 64(6):1403-15. PubMed ID: 26867490
[TBL] [Abstract] [Full Text] [Related]
13. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma.
Zhuang PY; Wang JD; Tang ZH; Zhou XP; Quan ZW; Liu YB; Shen J
BMC Cancer; 2015 Nov; 15():830. PubMed ID: 26525581
[TBL] [Abstract] [Full Text] [Related]
14. Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73.
Liang H; Block TM; Wang M; Nefsky B; Long R; Hafner J; Mehta AS; Marrero J; Gish R; Norton PA
Cancer Biomark; 2012; 11(4):161-71. PubMed ID: 23144154
[TBL] [Abstract] [Full Text] [Related]
15. JAK-STAT signaling in hepatic fibrosis.
Mair M; Blaas L; Österreicher CH; Casanova E; Eferl R
Front Biosci (Landmark Ed); 2011 Jun; 16(8):2794-811. PubMed ID: 21622209
[TBL] [Abstract] [Full Text] [Related]
16. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
Shanbhogue AK; Prasad SR; Takahashi N; Vikram R; Sahani DV
Radiology; 2011 Mar; 258(3):673-93. PubMed ID: 21339346
[TBL] [Abstract] [Full Text] [Related]
17. Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins.
Metz S; Wiesinger M; Vogt M; Lauks H; Schmalzing G; Heinrich PC; Müller-Newen G
J Biol Chem; 2007 Jan; 282(2):1238-48. PubMed ID: 17085445
[TBL] [Abstract] [Full Text] [Related]
18. C114 is a novel IL-11-inducible nuclear double-stranded RNA-binding protein that inhibits protein kinase R.
Yin Z; Haynie J; Williams BR; Yang YC
J Biol Chem; 2003 Jun; 278(25):22838-45. PubMed ID: 12679338
[TBL] [Abstract] [Full Text] [Related]
19. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases.
Kallen KJ
Biochim Biophys Acta; 2002 Nov; 1592(3):323-43. PubMed ID: 12421676
[TBL] [Abstract] [Full Text] [Related]
20. gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing junB mRNA transcription in the human hepatoma cell line, HepG2.
Varga VL; Fülöp AK; Holub MC; Tóth S; Szalai C; Falus A
Cell Biol Int; 2001; 25(8):835-40. PubMed ID: 11482910
[TBL] [Abstract] [Full Text] [Related]
[Next]
